Warnex Medical Laboratories Division now offers a test in the field of personalised medicine: K-ras mutation analysis for patients with colorectal cancer.
Colorectal cancer, also called colon cancer or large bowel cancer, includes cancerous growths in the colon, rectum and appendix.
Current treatment strategies include therapy targeting the epidermal growth factor receptor (EGFR).
However, studies have shown that a mutation in the K-ras gene gives rise to resistance to anti-EGFR therapy.
The incidence of K-ras mutations is about 40 per cent in colorectal cancer tumours.
K-ras mutation analysis provides physicians with valuable information while evaluating the use of EGFR-targeting compounds.
